Sponsored By
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel), a CD19-directed chimeric...
Read more
Verismo Therapeutics, a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T-cells, today announces that Penn and Verismo...
As the pipeline for cell therapies grows, manufacturers and CDMOs are looking to get in on the action. The Center...
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines,...
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build...
